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Post‑transplant diabetes mellitus, dyslipidaemias and 
overweight/obesity are extremely common among kidney 
transplant recipients (KTRs) and may undermine graft and 
recipient outcomes. With the joint position statement on the 
management of metabolic alterations in adult KTRs recently 
issued by the Italian Society of Nephrology, the Italian 
Society for Organ Transplantation and the Italian Diabetes 
Society [1], we sought to address the prevention, diagnosis 
and treatment of metabolic alterations in KTRs in order to 
support clinical decisions of professionals involved in the 
management of these patients. The joint position statement 
was meant to be an update of the 2009 Kidney Disease: 
Improving Global Outcomes (KDIGO) clinical practice 
guideline on the monitoring, management, and treatment 
of KTRs [2] and is based on the evidence published since 
then. When no new evidence was found, indications were 
based on expert opinion and relevant guidelines for the non‑
transplant population. In this commentary addressed to an 
audience of clinical nephrologists, we review the new state‑
ments and compare them with the previous recommenda‑
tions (Table 1) [2].
1. Screening for post-transplant diabetes mellitus Post‑
transplant diabetes mellitus had been previously 
addressed by the KDIGO guidelines and by a consen‑
sus of international experts [3]. Although postopera‑
tive hyperglycaemia may be predictive of subsequent 
alterations of glucose metabolism and should prompt 
close monitoring during follow‑up, a formal diagnosis 
of post‑transplant diabetes mellitus is best made when 
patients are stable on maintenance immunosuppression, 
with stable kidney graft function and in the absence of 
acute infections [3]. As compared with previous guide‑
lines [2], the joint position statement makes a distinction 
between the screening method (measurement of fasting 
plasma glucose, bedside capillary glucose, HbA1c or 
the oral glucose tolerance test [OGTT]) depending on 
the timing of assessment (perioperatively, in the first 
year after kidney transplantation or thereafter). Bedside 
capillary glucose is introduced as one of the suggested 
methods for the perioperative period, as it may be more 
sensitive than other tests in detecting patients at risk for 
post‑transplant diabetes. The joint position statement 
confirms the need for screening for post‑transplant dia‑
betes after modifying the immunosuppressive drug regi‑
men, and suggests screening when known risk factors 
are identified.
2. Managing post-transplant diabetes mellitus or diabetes 
present at transplantation Similar to previous guidelines 
[2], the joint position statement suggests considering 
modification of the immunosuppressive drug regimen. 
While little evidence was available to grade this state‑
ment when the KDIGO guidelines were issued, few 
studies have been published showing that early steroid 
withdrawal and switching from tacrolimus to cyclo‑
sporine (CsA) or from a calcineurin inhibitor‑based 
immunosuppressive regimen to a mammalian target of 
rapamycin inhibitor (mTORi)‑based immunosuppressive 
regimen might have some benefit on glucose metabo‑
lism, although more studies are needed to address these 
strategies. Data are also needed to assess the effects of 
reducing the dose of tacrolimus, CsA or corticoster‑
oids; replacing tacrolimus or CsA with mycophenolate 
mofetil or azathioprine; reducing the dose or discontinu‑
ing a mTORi. Importantly, the choice of modifying the 
immunosuppressive regimen should always be balanced 
against the risk of rejection and other potential adverse 
effects [3].
  For KTRs with pre‑existing diabetes or post‑trans‑
plant diabetes mellitus, a less stringent glycaemic tar‑
get (HbA1c 7–8% or 53–64 mmol/mol) is proposed, 
as compared with previous guidelines [2], based on a 
large retrospective study suggesting that hypoglycaemia 
is particularly detrimental to KTRs, who are at increased 
cardiovascular risk as compared with the general popu‑
lation. Self‑glucose monitoring should be encouraged. 
In the absence of studies specifically addressing this 
point, the same capillary glucose targets as for the gen‑
eral population with diabetes are suggested.
  The joint position statement also addresses the phar‑
macological management of diabetes, in both the inpa‑
tient and outpatient setting, more in depth than previ‑
ously done [3]. Insulin therapy is strongly recommended 
for persistent hyperglycaemia in the inpatient setting, 
and glycaemic targets are proposed to reduce the risk of 
adverse outcomes or subsequent post‑transplant diabetes 
mellitus. There was not sufficient evidence to guide rec‑
ommendations on the choice of glucose‑lowering agents 
in the outpatient setting, although the advent of novel 
drugs (i.e. glucagon‑like peptide 1 receptor agonists 
[GLP‑1RA] and sodium‑glucose cotransporter‑2 inhibi‑
tors [SGLT‑2i]) has boosted research in this field, and 
more evidence will likely become available soon. It was 
deemed reasonable to consider the choice of glucose‑
lowering agents according to patient characteristics, 
renal function and potential drug‑drug interactions, pre‑
ferring those with neutral or beneficial effects on cardio‑
vascualr and renal outcomes and that had already been 
tested in KTRs. No new studies were available on aspirin 
use for primary prevention in KTRs. As previously sug‑
gested [2], the use of aspirin can be considered for the 
primary prevention of cardiovascular disease based on 
risk factors, after balancing the risk for ischaemic events 
to that of bleeding. Further studies are needed since, in 
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the additional disadvantage of increasing the risk of 
bleeding and/or of delaying the time of biopsy.
  Data on lifestyle modifications on prevention and 
management of metabolic alterations in KTRs were and 
still are too sparse to support firm recommendations [2, 
3]. The joint position statement suggests encouraging 
lifestyle modifications including dietary changes, physi‑
cal exercise and, in overweight/obese patients, weight 
loss. This suggestion was not graded, due to the paucity 
and low quality of the available evidence. Very recently, 
the results of a randomised controlled trial were pub‑
lished, suggesting that a 6‑month active lifestyle inter‑
vention led by renal dieticians did not improve glucose 
metabolism as compared with passive lifestyle advice 
after kidney transplantation [4]. These findings should 
be taken with caution and not discourage physicians 
from providing lifestyle recommendations, as (1) both 
the active and passive interventions appeared to improve 
glucose metabolism to some extent; (2) the active inter‑
vention was associated with greater weight and fat mass 
loss, as well as with a trend towards lower incidence of 
post‑transplant diabetes mellitus. Lack of precise char‑
acterisation of baseline glucose metabolism (i.e. normal, 
impaired fasting glucose or impaired glucose tolerance), 
different degrees of renal function and the wide time‑
window following kidney transplantation (3–24 months) 
and body mass index range might help explain the lack 
of significant differences between the two interventions. 
Future studies should address these aspects and include 
patients at risk for developing post‑transplant diabetes 
mellitus.
3. Dyslipidaemias Studies specifically addressing the need 
for dyslipidaemia screening in adult KTRs are lacking. 
The joint position statement confirms that initial evalu‑
ation of the lipid profile is strongly recommended, as 
it is non‑invasive, inexpensive, and allows determining 
the type and severity of dyslipidaemia [5, 6]. Similar to 
previous guidelines, repeat evaluation of lipid profile 
is suggested after starting or adjusting treatment, until 
the target is achieved and annually thereafter, unless 
otherwise clinically indicated. While an LDL goal 
of < 100 mg/dL (< 2.6 mmol/L) was previously recom‑
mended for all KTRs [1], the joint position statement 
suggests achieving at least a ≥ 50% LDL‑C reduction 
from baseline in all KTRs, but sets different LDL goals 
based on the cardiovascular risk profile, suggesting that 
a lower goal of < 70 mg/dL [< 1.8 mmol/L] for KTRs 
at very high cardiovascular risk. These goals appear to 
be realistic and of potential benefit. While no specific 
indications on the pharmacological management of dys‑
lipidaemias were provided previously, the joint position 
statement suggests statins as first‑line lipid‑lowering 
treatment, as there is evidence that these agents might 
reduce cardiovascular events in KTRs. Use of ezetimibe 
or PCSK9 inhibitors may be considered as alternative 
or additional therapy to limit statin dose, but studies are 
needed to confirm the efficacy and safety of these agents 
in KTRs.
4. Obesity As in previous guidelines, assessment of obe‑
sity is recommended at each visit, although the strength 
of recommendation is weak due to the limited number 
of studies addressing this point. As waist circumfer‑
ence may predict long‑term survival better than BMI in 
KTRs, measuring it is suggested when weight and physi‑
cal appearance suggest obesity, but BMI is lower than 
the threshold for diagnosing obesity (< 30 kg/m2). At the 
time the KDIGO guidelines were published, only anec‑
dotal evidence was available to support the use of bari‑
atric surgery in the management of obese KTRs. Several 
reports have been published since then, although of low 
quality, and suggest that bariatric surgery in KTRs is 
effective for weight loss and associated with low rates of 
complications and mortality. Given the potential benefits 
of bariatric surgery on graft function, survival, and obe‑
sity‑related co‑morbidities, further studies are needed to 
better define indications, type of procedure and weight 
loss targets in the management of obese KTRs.
With the present joint position statement, we sought to 
provide practical indications to support clinicians in the 
management of KTRs. The choice of treatment, however, 
remains individual and depends on several factors such 
as the expected risk/benefit ratio for each patient, his/her 
preferences, and the availability of healthcare resources. A 
strength of this position statement is that the recommenda‑
tions stemmed from the joint effort of experts in diabetology 
and metabolism, nephrology, and kidney transplantation, but 
several gaps still need to be filled to guide decisions. The 
efficacy and safety of glucose‑ and lipid‑lowering drugs that 
have recently become available, the role of bariatric surgery 
and the identification of subpopulations of KTRs who would 
benefit the most from lifestyle interventions are just some 
of the important issues that should be urgently addressed.
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